FDA Accepts BLA for Datopotamab Deruxtecan in Pretreated Advanced Nonsquamous NSCLC
A BLA seeking the approval of datopotamab deruxtecan in pretreated nonsquamous non–small cell lung cancer is under review by the FDA.
Source: onclive.com
Dato Dxd News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Dato Dxd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Dato Dxd Today - Breaking & Trending Today
Expert Perspectives on the Latest TROPION-Lung01 Data
Edgardo Santos, MD, FACP, FCCP, provides expert insights into the latest data from the TROPION-Lung01 trial, emphasizing the potential implications of this information for treating patients with non-actionable biomarkers in NSCLC.
Source: onclive.com
Datopotamab Deruxtecan Prolongs PFS in HR+/HER2- Inoperable or Metastatic Breast Cancer
Datopotamab deruxtecan resulted in a statistically significant and clinically meaningful improvement in progression-free survival compared with chemotherapy among patients with previously treated, hormone receptor-positive/HER2-negative inoperable or metastatic breast cancer.
Source: onclive.com
Treatment Considerations With TROP2-Targeted Therapy
Clinical insights on best practices for treating patients with TROP2-targeted therapy.
Source: onclive.com
TROP2-Targeting Antibody-Drug Conjugates
The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.
Source: onclive.com